Loading organizations...
§ Private Profile · New York City, NY, USA
NOVOS is a technology company.
NOVOS operates as a longevity biotechnology company, developing a meticulously validated system aimed at extending human healthspan and longevity by directly addressing the biological processes of aging. The company designs science-based nutraceutical formulations and tools grounded in fundamental aging mechanisms, validating them through rigorous mechanistic studies, preclinical research, and human trials, emphasizing integrated systems over isolated ingredients.
Chris Mirabile, the company’s Founder and CEO, established NOVOS driven by a personal health journey and an insight into preventive medicine. After experiencing a brain tumor, Mirabile questioned the conventional medical approach of treating disease rather than proactively preserving health. This led him to collaborate with leading scientists and build NOVOS, committing to preserving health before age-related decline.
The company's solutions are utilized by individuals globally who seek to incorporate long-term health investment into their daily routines. NOVOS's overarching vision is to translate advanced aging research into clinically studied consumer solutions, empowering people to extend both their lifespan and overall quality of life through superior scientific rigor and elevated standards in the longevity field.
NOVOS has raised $9.0M across 2 funding rounds.
NOVOS has raised $9.0M in total across 2 funding rounds.
NOVOS has raised $9.0M in total across 2 funding rounds.
NOVOS's investors include Lorie&co, MizMaa Ventures, Resolute Ventures, Arkitekt Ventures, Arrive, Beckett Layne Ventures, BITKRAFT Ventures, Curie.Bio, E1 Ventures, Griffin Gaming Partners, Insight Partners, Khosla Ventures.
NOVOS has raised $9.0M across 2 funding rounds. Most recently, it raised $6.0M Seed in April 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2022 | $6M Seed | — | Lorie&co, MizMaa Ventures | Announced |
| Sep 1, 2021 | $3M Seed | Resolute Ventures | Arkitekt Ventures, Arrive, Beckett Layne Ventures, BITKRAFT Ventures, Curie.bio, E1 Ventures, Griffin Gaming Partners, Insight Partners, Khosla Ventures, Koch Fund, Lakeside Capital, Lightspeed Venture Partners, Operator Partners, Partners Resolute, Predictive VC, Henry Fertik, Assaf Wand, Kevin Colas, Oded Hermoni, Rashaun Williams, Florian Gschwandtner, Awesome People Ventures, Longevity Tech Fund | Announced |
NOVOS is a data- and research-driven longevity company founded in 2018, headquartered in New York City, that develops science-backed nutraceutical supplements targeting the root causes of aging to promote healthier aging and extend human lifespan.[3][5][6] It offers four powerful formulas with over 20 innovative ingredients, supported by 950+ studies, including NOVOS Core, which has shown an 18% lifespan increase in aged mice and up to 77% DNA protection in human skin cells from UV and chemo damage.[5][6] Serving consumers seeking anti-aging solutions, NOVOS simplifies wellness routines to enhance energy, cognition, skin health, and vitality, with over 10 million servings taken and users reporting 1.6 months less epigenetic age annually based on thousands of tests.[6] The company has raised under $5 million in funding and boasts a 4.7/5 user rating.[3][6]
NOVOS was founded in 2018 by longevity expert Chris Mirabile, emerging from rigorous four-year testing and formulation to launch its patent-pending supplement line in a beta and introductory phase before full debut.[3][6] The idea stemmed from breakthroughs in aging science, positioning NOVOS as the pioneer in consumer longevity by creating the first formula addressing 12 fundamental causes of aging, backed by deep biotech expertise including genomics, personalized medicine, and gene therapy.[3][5] Early traction included successful beta testing, high user satisfaction, and scientific validation like epigenetic age reductions via the DunedinPACE algorithm from Duke and Columbia researchers, humanizing its mission through real-world longevity impacts.[5][6]
NOVOS rides the explosive longevity biotech trend, fueled by advances in epigenetics, AI-driven aging clocks like DunedinPACE, and consumer demand for preventive health amid rising life expectancies and chronic disease burdens.[5][6] Timing is ideal post-2018 launch, aligning with post-pandemic wellness booms and $5M+ funding in anti-aging, where market forces like genomic sequencing democratization and personalized medicine favor scalable nutraceuticals over expensive therapies.[3][5] It influences the ecosystem by democratizing elite longevity science for consumers, bridging academic research (e.g., mouse/human cell studies) to mainstream use, and competing with NAD+ supplements while pioneering multi-cause aging interventions.[6]
NOVOS is poised to dominate consumer longevity with expanding evidence (e.g., more epigenetic data, human trials) and formula iterations amid trends like AI-optimized nutraceuticals and integrated wearables for real-time aging tracking.[5][6] Regulatory tailwinds for supplements and partnerships with biotech could scale it beyond <$5M revenue, potentially evolving into a full-stack wellness platform influencing how millions "live younger longer."[3][6] As aging science accelerates, NOVOS's root-cause approach positions it to redefine healthy aging, tying back to its core promise of evidence-backed vitality for all.